U.S. Markets open in 8 hrs 29 mins

Geron Corporation (GERN)

NASDAQ Global Select - NASDAQ Global Select Delayed Price. Currency in USD
Add to watchlist
1.99-0.04 (-1.97%)
At close: 4:00PM EDT
People also watch
STEMEXELINCYARIACTIC
  • A
    Anne S
    Anne S

    EU Clinical Trials EudraCT Number: 2015-002874-19 (MDS CT)

    IMO, this is why Janssen is willing to submit Part 1 of Imerge at a major medical conference.

    This is Part 2 of the MDS CT:

    Part 2: To compare the efficacy, in terms of RBC TI, of imetelstat to placebo in transfusion dependent subjects with low or intermediate-1 risk MDS that is relapsed/refractory to ESA treatment.

    Secondary objectives of the trial
    - To assess the safety of imetelstat in subjects with MDS
    - To assess the time to RBC TI and duration of RBC TI
    - To assess the rate of hematologic improvement
    - To assess the rates of CR or PR
    - To assess OS
    - To assess time to progression to AML
    - To assess the rate and amount of supportive care, including transfusions and myeloid growth factors
    - To evaluate the pharmacokinetics and immunogenicity of imetelstat in subjects with MDS
    - To assess the effect of imetelstat treatment on patient reported outcomes (PROs)
    - To assess the effect of treatment on medical resource utilization

    https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002874-19/DE

    Clinical Trials Register
    www.clinicaltrialsregister.eu
  • R
    Ryan W
    Ryan W
    As depressed as anyone to see this stock at $1.99 - but put simply, the pps will not be a factor in whether I sell - I am in to see the results of these trials. I still believe that 'efficacy trends' means efficacy, as already produced in Mayo trials 5 years ago...
  • e
    early retirement
    early retirement
    Trump never would have gotten elected if the politicians had not failed this country so miserably the last many years. That is how Trump got elected and that is where the real blame lies is on our career politicians that look after themselves and their gold-plated retirements and a gold-plated Healthcare.
  • S
    Steve
    Steve
    Geron is dirt cheap back up your truck and load up.
  • S
    StevenW
    StevenW

    How can the Fool possibly know a decision is looming by the end of Sept? Fake news? Is this a ploy to let some institutional holders out and leave us bagholders holding the bag of schnitzels? Opinions?

    We won't have to wait too much longer to get a better handle on Geron's future. By the end of next September, Johnson & Johnson will make a decision about whether or not to continue developing imetelstat based on results from the recently modified study. If this little biotech's partner gives the thumbs up, you probably won't be able to buy its shares for less than $5 anymore.

    https://www.fool.com/investing/2017/08/19/3-top-biotech-stocks-under-5.aspx?yptr=yahoo

    3 Top Biotech Stocks Under $5 @themotleyfool #stocks $JNJ, $GSK, $GERN, $AGEN, $INCY, $RIGL
    www.fool.com
  • S
    Sam
    Sam
    J&J will announce a huge Buyout on GERON sooner than later...
    Imageyourreactiongifs
  • M
    Mangymutt
    Mangymutt
    repost from seeking alpha

    black,
    How you doing on holding chippy and co. accountable? I mean really, you been singing that tune for years and I have to ask "how's that work'n for you?"
  • T
    TrailBlazer7
    TrailBlazer7
    Racist Steve Bannon has resigned from the Trump team in disgrace. Stock market reacts positively. Now we just need the orange clown to quit and America will be great again.
  • M
    Mangymutt
    Mangymutt
    5 BILLION guys $32 PPS
  • g
    georgek
    georgek
    W/ the 20/80 split on retail sales of IMET, I cannot imagine that JnJ would offer a buy out. They already have the golden goose locked up and will so for years. Opting in will cost 35M, a milestone payment, offering a buy out would cost 1/2 a billion at least. Where's the financial logic? Down the road, if the "billion dollar block buster" forecast by JnJ for IMET holds true, the 20%....200M a year is a large chunk of change and with those kinds of earnings would easily get the stock into the double digits. But buyout?
  • h
    hayflicklim
    hayflicklim
    new patent
    ( 1 of 177 )
    United States Patent 9,732,114
    Gryaznov , et al. August 15, 2017
    Compounds having anti-adhesive effects on cancer cells

    Abstract
    Compounds of the form O-(x-L)n, where O is an oligonucleoside having at least a plurality of N3'.fwdarw.P5' thiophosphoramidate (NPS) internucleoside linkages, a conjugated lipid moiety L, and at least one G-rich sequence motif as described, are effective to morphologically alter and reduce adhesion of cancer cells.

    Inventors: Gryaznov; Sergei M. (San Mateo, CA), Shay; Jerry W. (Dallas, TX), Wright; Woodring (Arlington, TX)
    Applicant:
    Name City State Country Type

    Gryaznov; Sergei M.
    Shay; Jerry W.
    Wright; Woodring
    San Mateo
    Dallas
    Arlington
    CA
    TX
    TX
    US
    US
    US
    Assignee: GERON CORPORATION (Menlo Park, CA)
    BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (Austin, TX)
    Family ID: 1000002778857
    Appl. No.: 14/336,443
    Filed: July 21, 2014
    Prior Publication Data
  • S
    Sam
    Sam
    J&J transferred $20 Billions dollars to the USA....
    Imageasktheboywholived
  • L
    Lonesome Polecat
    Lonesome Polecat

    What a dumb arzzzzz

    https://talkingpointsmemo.com/livewire/trump-looks-at-sun-during-solar-eclipse

    Trump Looks At The Sun During Full Solar Eclipse Despite Shouted Warning
    President Donald Trump’s administration on Monday took a moment in the afternoon to observe the first total solar eclipse to...
    talkingpointsmemo.com
  • J
    Joan D.
    Joan D.
    Opt-in or Buy Out you gotta be in it to win it!!! Dragging us through the mud won't last forever!!!
  • l
    larrythelumberjack
    larrythelumberjack
    Where are you ER? You have told us every week for 10 years that GERN was about to surge! I guess you were right, it surged right into the sewer!
  • P
    Paul
    Paul
    A bunch of sniffing Trump haters on this MB.
  • A
    Anne S
    Anne S

    Myelodysplastic Syndrome (MDS Last Updated August 16, 2017

    Recruiting
    86 sites

    Seems like Janssen is waiting for the FDA go ahead.

    http://globaltrialfinder.janssen.com/trial/CR107947-2

    Study to Evaluate Imetelstat (JNJ-63935937) in Subjects with International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) | Global Trial Finder
    The purpose of this study is to evaluate the efficacy and safety of imetelstat in transfusion dependent participants with low or intermediate-1 risk myelodysplastic syndrome (MDS) that is relapsed/refractory to erythropoiesis-stimulating agent (ESA)
    globaltrialfinder.janssen.com
  • e
    early retirement
    early retirement
    Shorts need to buy up 33 million GERN shares and Johnson and Johnson just called GERN'S drug 1 of Johnson and Johnson's top 6 future money makers.
  • M
    Mangymutt
    Mangymutt
    Let's see how hard black works today on a $2. stock.
  • H
    Hairypottter9
    Hairypottter9
    They're reporting at ASH, we already know what they're going to say. Their drug works better than what's out there. It even works better for people as a front line drug for MDS and MF! And it cures cancer for some with MF. Buying. Buying a lot. I'm going to turn every $1 I put into GERN into $50.

    BUY BUY BUY BUY BUY!!!!!

    JMHO